# Zero Point Five Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/zero-point-five-therapeutics

- Industry: Biotechnology
- Headquarters: Baltimore, US
- Website: www.zeropointfivetherapeutics.com
- Total disclosed funding: $12M
- Latest round: Series C (Apr 2, 2025)
- Investors on record: 2

## About

Based in Maryland, US and founded in 2018, Zero point five therapeutics operates as a biotechnology company that focuses on developing ZP5-9676, a drug used to treat neglected tropical diseases. The company was founded by its CEO Joseph Amprey and CSO Helen Pentikis. In April 2025, Zero Point Five Therapeutics, Inc. raised USD 4.30 million in series C funding from returning investor TEDCO and other unspecified investors. The biotechnology company develops a drug to fight against diseases caused by whipworms, tapeworms, and hookworms. It is a single-dose therapy that treats soil-transmitted helminths which include Necator americanus, roundworm, whipworm, etc. The company will use the April 2025 funding to support its research and development efforts.

## Funding rounds

- Series C, Apr 2, 2025, $4.3M — TEDCO
- Series B, Jun 27, 2023, $7.2M — Portfolia

## Investors

- Portfolia (https://capitalatlas.ai/funds/portfolia) — Series B
- TEDCO (https://capitalatlas.ai/funds/tedco) — Series C